🎉 M&A multiples are live!
Check it out!

Protara Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Protara Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Protara Therapeutics Overview

About Protara Therapeutics

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Founded

2006

HQ

United States of America
Employees

33

Website

protaratx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$13.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Protara Therapeutics Financials

Protara Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Protara Therapeutics achieved revenue of n/a and an EBITDA of -$48.8M.

Protara Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Protara Therapeutics valuation multiples based on analyst estimates

Protara Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$43.3M -$48.8M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$66.0M -$40.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Protara Therapeutics Stock Performance

As of April 15, 2025, Protara Therapeutics's stock price is $4.

Protara Therapeutics has current market cap of $152M, and EV of -$13.6M.

See Protara Therapeutics trading valuation data

Protara Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$13.6M $152M XXX XXX XXX XXX $-2.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Protara Therapeutics Valuation Multiples

As of April 15, 2025, Protara Therapeutics has market cap of $152M and EV of -$13.6M.

Protara Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Protara Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Protara Therapeutics and 10K+ public comps

Protara Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$13.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.3x XXX XXX XXX
P/E -3.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Protara Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Protara Therapeutics Valuation Multiples

Protara Therapeutics's NTM/LTM revenue growth is n/a

Protara Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.5M for the same period.

Over next 12 months, Protara Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Protara Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Protara Therapeutics and other 10K+ public comps

Protara Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Protara Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Protara Therapeutics M&A and Investment Activity

Protara Therapeutics acquired  XXX companies to date.

Last acquisition by Protara Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Protara Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Protara Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Protara Therapeutics

When was Protara Therapeutics founded? Protara Therapeutics was founded in 2006.
Where is Protara Therapeutics headquartered? Protara Therapeutics is headquartered in United States of America.
How many employees does Protara Therapeutics have? As of today, Protara Therapeutics has 33 employees.
Who is the CEO of Protara Therapeutics? Protara Therapeutics's CEO is Mr. Jesse Shefferman, PhD.
Is Protara Therapeutics publicy listed? Yes, Protara Therapeutics is a public company listed on NAS.
What is the stock symbol of Protara Therapeutics? Protara Therapeutics trades under TARA ticker.
When did Protara Therapeutics go public? Protara Therapeutics went public in 2020.
Who are competitors of Protara Therapeutics? Similar companies to Protara Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Protara Therapeutics? Protara Therapeutics's current market cap is $152M
Is Protara Therapeutics profitable? Yes, Protara Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.